EA200970255A1 - Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение - Google Patents
Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применениеInfo
- Publication number
- EA200970255A1 EA200970255A1 EA200970255A EA200970255A EA200970255A1 EA 200970255 A1 EA200970255 A1 EA 200970255A1 EA 200970255 A EA200970255 A EA 200970255A EA 200970255 A EA200970255 A EA 200970255A EA 200970255 A1 EA200970255 A1 EA 200970255A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies
- influenza virus
- binding molecules
- neutralize
- influenza
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 5
- 206010064097 avian influenza Diseases 0.000 abstract 3
- 206010022000 influenza Diseases 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/00061—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16061—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
Настоящее изобретение относится к связывающим молекулам, таким как моноклональные антитела человека, которые связываются с вирусом гриппа H5N1 и обладают нейтрализующей активностью в отношении вируса гриппа H5N1. Настоящее изобретение относится к молекулам нуклеиновых кислот, кодирующим антитела, их последовательностям и композициям, включающим указанные антитела, а также к способам идентификации или получения антител. Указанные антитела могут быть использованы для диагностики, профилактики и/или лечения гриппа, вызываемого вирусом гриппа H5N1. В предпочтительном варианте осуществления изобретения указанные антитела обеспечивают перекрестную защиту in vivo от разных подтипов вируса гриппа, что позволяет предотвратить и/или лечить грипп, вызываемый подтипами вируса гриппа на основе Н5, Н2, Н6, Н9 и H1.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84293006P | 2006-09-07 | 2006-09-07 | |
EP06120316 | 2006-09-07 | ||
EP06120644 | 2006-09-14 | ||
EP06125107 | 2006-11-30 | ||
EP07111235 | 2007-06-28 | ||
PCT/EP2007/059356 WO2008028946A2 (en) | 2006-09-07 | 2007-09-06 | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200970255A1 true EA200970255A1 (ru) | 2009-10-30 |
EA017203B1 EA017203B1 (ru) | 2012-10-30 |
Family
ID=39027173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200970255A EA017203B1 (ru) | 2006-09-07 | 2007-09-06 | Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение |
Country Status (16)
Country | Link |
---|---|
US (5) | US8192927B2 (ru) |
EP (2) | EP2059532B1 (ru) |
JP (2) | JP5161882B2 (ru) |
KR (1) | KR101485197B1 (ru) |
AU (1) | AU2007293662B2 (ru) |
CA (1) | CA2663388C (ru) |
EA (1) | EA017203B1 (ru) |
HK (1) | HK1126799A1 (ru) |
HR (1) | HRP20130163T1 (ru) |
IL (2) | IL197390A (ru) |
MX (1) | MX2009002174A (ru) |
MY (1) | MY170607A (ru) |
NO (1) | NO20091321L (ru) |
PL (1) | PL2059532T3 (ru) |
WO (1) | WO2008028946A2 (ru) |
ZA (1) | ZA200901171B (ru) |
Families Citing this family (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
PT2314629E (pt) | 2002-07-18 | 2014-01-22 | Merus B V | Produção recombinante de misturas de anticorpos |
ES2408582T3 (es) | 2003-05-30 | 2013-06-21 | Merus B.V. | Biblioteca de Fab para la preparación de una mezcla de anticuerpos |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
KR101206206B1 (ko) * | 2003-07-22 | 2012-11-29 | 크루셀 홀란드 비.브이. | 사스-코로나바이러스에 대한 결합분자 및 그것의 용도 |
DK1749029T3 (da) | 2004-05-27 | 2011-06-06 | Crucell Holland Bv | Bindemolekyler, der kan neutralisere rabiesvirus, og anvendelser deraf |
JP4852046B2 (ja) * | 2004-10-12 | 2012-01-11 | クルセル ホランド ベー ヴェー | 癌の治療及び検出に用いる結合分子 |
US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
AU2006245734C1 (en) | 2005-05-12 | 2012-05-24 | Crucell Holland B.V. | Host cell specific binding molecules capable of neutralizing viruses and uses thereof |
US8148085B2 (en) | 2006-05-15 | 2012-04-03 | Sea Lane Biotechnologies, Llc | Donor specific antibody libraries |
EA031202B1 (ru) | 2006-06-06 | 2018-11-30 | Янссен Вэксинс Энд Превеншн Б.В. | Антитело человека, обладающее фагоцитарной активностью против стафилококков, и его применение |
MY170607A (en) | 2006-09-07 | 2019-08-20 | Crucell Holland Bv | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
WO2008110937A2 (en) * | 2007-03-13 | 2008-09-18 | Humabs Llc | Antibodies against h5n1 strains of influenza a virus |
MX2009009912A (es) | 2007-03-27 | 2010-01-18 | Sea Lane Biotechnologies Llc | Constructos y colecciones que comprenden secuencias de cadena ligera sustitutas de anticuerpos. |
EP2036045A1 (en) * | 2007-07-11 | 2009-03-18 | Cairos technologies AG | Video tracking method and appartus arrangement for performing the method |
JP5490695B2 (ja) * | 2007-09-13 | 2014-05-14 | テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド | インフルエンザウイルスh5亜型からのヘマグルチニンに特異的なモノクローナル抗体およびそれらの使用 |
JP5490696B2 (ja) | 2007-09-13 | 2014-05-14 | テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド | インフルエンザウイルスh5亜型またはn1亜型からのヘマグルチニンおよびノイラミニダーゼに特異的なモノクローナル抗体ならびにそれらの使用 |
EP2222701B1 (en) | 2007-12-06 | 2017-11-01 | Dana-Farber Cancer Institute, Inc. | Antibodies against influenza virus and methods of use thereof |
ITTO20080204A1 (it) | 2008-03-17 | 2009-09-18 | Pomona Biotechnologies Llc | Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a |
WO2009121004A2 (en) | 2008-03-28 | 2009-10-01 | Sea Lane Biotechnologies, Llc | Neutralizing molecules to viral antigens |
CN101550188B (zh) * | 2008-04-01 | 2012-05-02 | 南方医科大学 | H5亚型禽流感病毒h5n1血凝素单克隆抗体及其核苷酸序列和制备方法 |
ITTO20080398A1 (it) | 2008-05-27 | 2009-11-28 | Pomona Biotechnologies Llc | Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1 |
JP2011528902A (ja) * | 2008-07-25 | 2011-12-01 | インスティテュート・フォー・リサーチ・イン・バイオメディシン | 抗a型インフルエンザウイルス中和抗体およびその使用 |
US8871207B2 (en) | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
GB0818356D0 (en) * | 2008-10-07 | 2008-11-12 | Istituto Superiore Di Sanito | Antibodies |
TWI381848B (zh) * | 2008-10-20 | 2013-01-11 | Imclone Llc | 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物 |
US9347043B2 (en) | 2008-10-22 | 2016-05-24 | Institute For Research In Biomedicine | Methods for producing antibodies from plasma cells |
BRPI0921845A2 (pt) * | 2008-11-12 | 2019-09-17 | Medimmune Llc | formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata |
AU2008365616A1 (en) * | 2008-12-24 | 2011-08-11 | Temasek Life Sciences Laboratory Limited | Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza A viruses and uses thereof |
CA2787099A1 (en) | 2009-03-30 | 2010-10-14 | Anice C. Lowen | Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof |
CA2760553A1 (en) * | 2009-04-30 | 2010-11-04 | Jr. James E. Crowe | Monoclonal antibodies to influenza h1n1 virus and uses thereof |
BRPI1012749B1 (pt) * | 2009-05-11 | 2022-01-11 | Janssen Vaccines & Prevention B.V. | Anticorpo monoclonal humano, seu uso e seu método de produção, imunoconjugado, e composição farmacêutica |
AU2010249046A1 (en) | 2009-05-13 | 2011-12-01 | Sea Lane Biotechnologies, Llc | Neutralizing molecules to influenza viruses |
JP5941841B2 (ja) | 2009-05-26 | 2016-06-29 | アイカーン スクール オブ メディシン アット マウント サイナイ | 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用 |
AU2010282415A1 (en) * | 2009-08-14 | 2012-03-08 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of influenza |
US9458226B2 (en) | 2009-10-09 | 2016-10-04 | Emory University | Recombinant antibodies against H1N1 influenza |
JP6210685B2 (ja) * | 2010-01-27 | 2017-10-11 | マサチューセッツ インスティテュート オブ テクノロジー | 標的化された広域スペクトルのインフルエンザ中和のための操作されたポリペプチド剤 |
MX342716B (es) | 2010-02-18 | 2016-10-11 | Sinai School Medicine | Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza. |
WO2011111966A2 (en) * | 2010-03-08 | 2011-09-15 | Celltrion, Inc. | Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses |
CA2792537A1 (en) | 2010-03-30 | 2011-10-06 | Mount Sinai School Of Medicine | Influenza virus vaccines and uses thereof |
CN102241768B (zh) * | 2010-05-14 | 2013-12-25 | 中国科学院上海生命科学研究院 | 一种抗甲型h1n1流感病毒血凝素蛋白的抗体 |
WO2011160083A1 (en) * | 2010-06-17 | 2011-12-22 | Trellis Bioscience, Inc. | Antibodies useful in passive influenza immuization |
EP2596017B1 (en) | 2010-07-22 | 2019-04-03 | John W. Schrader | Cross-protective antibody against influenza viral infection |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
JP2013540701A (ja) * | 2010-08-12 | 2013-11-07 | セラクローン サイエンシーズ, インコーポレイテッド | 抗赤血球凝集素抗体組成物およびその使用方法 |
US9534042B2 (en) | 2010-09-03 | 2017-01-03 | Fujita Health University | Influenza virus-neutralizing antibody and screening method therefor |
US8883171B2 (en) | 2010-09-14 | 2014-11-11 | University of Pittsburgh—of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for influenza |
HUE058896T2 (hu) | 2010-10-01 | 2022-09-28 | Modernatx Inc | N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai |
WO2012096994A2 (en) * | 2011-01-10 | 2012-07-19 | Emory University | Antibodies directed against influenza |
BR112013020743A2 (pt) * | 2011-02-14 | 2016-10-18 | Theraclone Sciences Inc | composições e métodos para a terapia e diagnóstico de influenza |
WO2012118903A2 (en) * | 2011-03-01 | 2012-09-07 | Amgen Inc. | Bispecific binding agents |
US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
JP6024025B2 (ja) | 2011-05-02 | 2016-11-09 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 少容量投与用のアロタイプ選択抗体の限外濾過濃縮 |
JP6113155B2 (ja) | 2011-06-20 | 2017-04-12 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 計算で最適化した広い反応性を示すh1n1インフルエンザの抗原 |
MX346206B (es) | 2011-07-14 | 2017-03-09 | Crucell Holland Bv | Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b. |
DK3418300T3 (da) | 2011-07-18 | 2020-12-07 | Inst Res Biomedicine | Neutralisering af anti-influenza-a-virusantistoffer og anvendelser deraf |
EP2736928B1 (en) | 2011-07-28 | 2019-01-09 | i2 Pharmaceuticals, Inc. | Sur-binding proteins against erbb3 |
WO2013033319A2 (en) * | 2011-08-30 | 2013-03-07 | The Board Of Trustees Of The Leland Stanford Junior University | A cluster of neutralizing antibodies to hepatitis c virus |
GB201115214D0 (en) | 2011-09-02 | 2011-10-19 | Health Prot Agency | Influenza virus antibody compositions |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP2758075B1 (en) | 2011-09-20 | 2023-05-03 | Icahn School of Medicine at Mount Sinai | Influenza virus vaccines and uses thereof |
CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
RS62993B1 (sr) | 2011-10-03 | 2022-03-31 | Modernatx Inc | Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe |
AU2012326025B2 (en) * | 2011-10-18 | 2017-08-31 | Emory University | Antibodies directed against influenza |
SG11201402633UA (en) | 2011-11-28 | 2014-09-26 | Crucell Holland Bv | Influenza virus vaccines and uses thereof |
KR20140112495A (ko) | 2011-12-02 | 2014-09-23 | 에임 쎄라퓨틱스 비.브이. | 인플루엔자 a 바이러스 특이적 항체 |
CA2861515A1 (en) | 2011-12-05 | 2013-06-13 | Trellis Bioscience, Llc | Antibodies useful in passive influenza immunization |
KR101749316B1 (ko) | 2011-12-15 | 2017-06-21 | (주) 에이프로젠 | H1n1―감염된 환자들로부터 유도된 매우 잠재력 있는 넓은-스펙트럼 중화 단일클론 항체 및 이를 포함하는 바이러스의 치료용 조성물 |
CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
US9975956B2 (en) | 2011-12-22 | 2018-05-22 | I2 Pharmaceuticals, Inc. | Surrogate binding proteins which bind DR4 and/or DR5 |
WO2013119683A1 (en) | 2012-02-07 | 2013-08-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses |
CA2863949C (en) | 2012-02-13 | 2021-06-29 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for human and avian h5n1 influenza |
WO2013132007A1 (en) | 2012-03-08 | 2013-09-12 | Crucell Holland B.V. | Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof |
RU2639551C2 (ru) | 2012-03-30 | 2017-12-21 | Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн | Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вирусов гриппа h5n1 и h1n1 |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
NZ772318A (en) | 2012-04-20 | 2023-06-30 | Merus Nv | Methods and means for the production of ig-like molecules |
US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
EP2712626A1 (en) * | 2012-09-28 | 2014-04-02 | Fabentech | Passive immunisation against influenza, in particular H5N1 |
MX2015005860A (es) | 2012-11-13 | 2015-08-10 | Genentech Inc | Anticuerpos de antihemaglutinina y metodo de uso. |
EP4074834A1 (en) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Terminally modified rna |
US9309290B2 (en) | 2012-11-27 | 2016-04-12 | University of Pittsburgh—of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for H1N1 influenza |
NZ627796A (en) | 2012-12-18 | 2017-07-28 | Icahn School Med Mount Sinai | Influenza virus vaccines and uses thereof |
AU2014236508A1 (en) | 2013-03-14 | 2015-09-17 | Contrafect Corporation | Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy |
WO2014159960A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
WO2014152946A2 (en) | 2013-03-14 | 2014-09-25 | University Of Washington Through Its Center For Commercialization | Polypeptides for treating and/or limiting influenza infection |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
CN104098692B (zh) | 2013-04-02 | 2018-11-30 | 厦门大学 | 识别流感病毒血凝素蛋白ha1结构域的广谱单克隆抗体 |
CA2913859C (en) | 2013-05-30 | 2021-11-30 | Crucell Holland B.V. | Influenza virus vaccines and uses thereof |
EP3037819A4 (en) * | 2013-08-23 | 2017-03-29 | Fujita Health University | Method of determining resistance to influenza virus |
EP3037533A4 (en) | 2013-08-23 | 2017-07-05 | Fujita Health University | Anti-influenza virus-neutralizing antibody |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
DK3052192T3 (da) | 2013-10-02 | 2020-09-28 | Medimmune Llc | Neutraliserende anti-influenza a-antistoffer og anvendelser deraf |
MX2016004249A (es) | 2013-10-03 | 2016-11-08 | Moderna Therapeutics Inc | Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad. |
US20160264648A1 (en) * | 2013-11-06 | 2016-09-15 | Osaka University | Antibody having broad neutralization activity against group 1 influenza a viruses |
US10639370B2 (en) | 2014-02-04 | 2020-05-05 | Contrafect Corporation | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof |
EP3102598A2 (en) | 2014-02-04 | 2016-12-14 | Contrafect Corporation | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof |
KR102378289B1 (ko) | 2014-02-10 | 2022-03-23 | 아이쥐엠 바이오사이언스 인코포레이티드 | IgA 다중-특이적 결합 분자 |
WO2015143194A2 (en) * | 2014-03-19 | 2015-09-24 | Dana-Farber Cancer Institute, Inc. | Immunogenetic restriction on elicitation of antibodies |
PT3134131T (pt) | 2014-04-23 | 2022-03-24 | Modernatx Inc | Vacinas de ácidos nucleicos |
CN107074912B (zh) | 2014-07-10 | 2021-10-29 | 扬森疫苗与预防公司 | 流行性感冒病毒疫苗及其用途 |
BR112017000257A2 (pt) | 2014-07-10 | 2017-10-31 | Janssen Vaccines & Prevention Bv | vacinas contra o vírus da gripe e usos das mesmas |
RU2739952C2 (ru) | 2014-07-15 | 2020-12-30 | МЕДИММЬЮН, ЭлЭлСи | Нейтрализующие антитела к вирусу гриппа b и пути их применения |
TWI702229B (zh) | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
JP2018504412A (ja) | 2015-01-23 | 2018-02-15 | アイカーン スクール オブ メディシン アット マウント サイナイ | インフルエンザウイルスワクチン接種レジメン |
EP3253787B1 (en) | 2015-02-05 | 2020-10-07 | Janssen Vaccines & Prevention B.V. | Human neutralizing antibodies binding to influenza neuraminidase |
CA2975655C (en) | 2015-02-05 | 2023-09-19 | Janssen Vaccines & Prevention B.V. | Binding molecules directed against influenza hemagglutinin and uses thereof |
EA201792482A1 (ru) | 2015-05-11 | 2018-02-28 | Янссен Вэксинс Энд Превеншн Б.В. | Соединения-пептидомиметики, нейтрализующие вирус гриппа |
AU2016271323B2 (en) | 2015-06-01 | 2022-08-25 | Medimmune, Llc | Neutralizing anti-influenza binding molecules and uses thereof |
WO2017083627A1 (en) | 2015-11-13 | 2017-05-18 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
SG11201805001UA (en) | 2016-01-13 | 2018-07-30 | Medimmune Llc | Method of treating influenza a |
EP3423484B1 (en) | 2016-03-01 | 2021-01-13 | Janssen Vaccines & Prevention B.V. | Human neutralizing antibodies binding to influenza b neuraminidase |
US11266734B2 (en) | 2016-06-15 | 2022-03-08 | Icahn School Of Medicine At Mount Sinai | Influenza virus hemagglutinin proteins and uses thereof |
KR101835009B1 (ko) | 2016-08-19 | 2018-03-07 | 주식회사 하이딥 | 터치 입력 장치 |
JP7265984B2 (ja) | 2016-10-21 | 2023-04-27 | アディマブ, エルエルシー | 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法 |
KR20190103147A (ko) | 2016-10-21 | 2019-09-04 | 아디맵 엘엘씨 | 항-호흡기 세포융합 바이러스 항체, 그리고 이의 생성 방법 및 사용 방법 |
WO2018075974A2 (en) * | 2016-10-21 | 2018-04-26 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
CN110234337A (zh) | 2016-10-27 | 2019-09-13 | 扬森疫苗与预防公司 | 中和流感病毒的化合物 |
US11566064B2 (en) | 2017-01-27 | 2023-01-31 | National Research Council Of Canada | Hemagglutinin-specific antibodies and uses thereof |
EP3577107A1 (en) | 2017-02-02 | 2019-12-11 | Janssen Vaccines & Prevention B.V. | Piperazine derivatives for influenza virus inhibition |
WO2018141854A1 (en) | 2017-02-02 | 2018-08-09 | Janssen Vaccines & Prevention B.V. | Piperazine derivatives for influenza virus inhibition |
SG11201907299XA (en) | 2017-02-08 | 2019-09-27 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
ES2955074T3 (es) | 2017-02-20 | 2023-11-28 | Dragonfly Therapeutics Inc | Proteínas que se unen a HER2, NKG2D Y CD16 |
WO2018187074A1 (en) | 2017-04-03 | 2018-10-11 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
WO2018187706A2 (en) | 2017-04-07 | 2018-10-11 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
WO2019035630A2 (ko) * | 2017-08-14 | 2019-02-21 | 사회복지법인 삼성생명공익재단 | 인간 상피 성장 인자 수용체 변이체 ⅲ에 결합하는 항체 및 그의 항체 단편 |
US10501539B2 (en) * | 2017-09-15 | 2019-12-10 | Lentigen Technology Inc. | Compositions and methods for treating cancer with anti-CD19 immunotherapy |
HRP20220980T1 (hr) | 2018-01-23 | 2022-11-11 | Janssen Vaccines & Prevention B.V. | Cjepiva protiv virusa influence i njihova uporaba |
WO2019147867A1 (en) | 2018-01-26 | 2019-08-01 | Regeneron Pharmaceuticals, Inc. | Human antibodies to influenza hemagglutinin |
WO2019157366A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
CN111057718A (zh) * | 2018-10-17 | 2020-04-24 | 南京大学 | 一种稳定表达绿色荧光蛋白的egfp-sp2/0细胞株及其构建方法 |
KR102113302B1 (ko) * | 2018-12-24 | 2020-05-20 | 원광대학교산학협력단 | 상보성결정부 기반 조류 인플루엔자 바이러스의 h5 아형에 특이적으로 결합하는 펩티드 및 이의 용도 |
JP2022521819A (ja) | 2019-03-25 | 2022-04-12 | ビステラ, インコーポレイテッド | インフルエンザを処置および予防するための組成物および方法 |
CA3152957A1 (en) | 2019-09-05 | 2021-03-11 | Janssen Vaccines & Prevention B.V. | Influenza virus vaccines and uses thereof |
US11642407B2 (en) | 2020-02-28 | 2023-05-09 | Massachusetts Institute Of Technology | Identification of variable influenza residues and uses thereof |
CN111440228B (zh) * | 2020-03-09 | 2021-08-24 | 扬州大学 | 多种亚型流感病毒ha2蛋白共同抗原表位、抗体、鉴定方法和应用 |
WO2021201677A1 (en) | 2020-04-01 | 2021-10-07 | Kiadis Pharma Intellectual Property B.V. | Compositions and methods targeting influenza |
US20210325367A1 (en) * | 2020-04-20 | 2021-10-21 | Satish Mahna | Controlled Exposure to Pathogens for Generating Immunity |
CN116761605A (zh) | 2021-02-04 | 2023-09-15 | 四川海思科制药有限公司 | Ha抑制剂化合物的盐及晶型 |
WO2022232557A1 (en) * | 2021-04-30 | 2022-11-03 | Adagio Therapeutics, Inc. | Compounds specific to coronavirus s protein and uses thereof |
WO2024104947A2 (en) | 2022-11-14 | 2024-05-23 | Janssen Vaccines & Prevention B.V. | Influenza b virus vaccines and uses thereof |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4625015A (en) * | 1982-08-23 | 1986-11-25 | Scripps Clinic & Research Foundation | Broad spectrum influenza antisera |
ZA836080B (en) * | 1982-08-23 | 1984-04-25 | Scripps Clinic Res | Broad spectrum influenza antisera |
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
NL9101953A (nl) | 1991-11-21 | 1993-06-16 | Seed Capital Investments | Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen. |
JP3037554B2 (ja) * | 1993-04-20 | 2000-04-24 | 寳酒造株式会社 | 免疫原性人工ポリペプチド |
US5589174A (en) * | 1992-09-17 | 1996-12-31 | Takara Shuzo Co., Ltd. | Anti-human influenza virus antibody |
JP3061960B2 (ja) * | 1992-09-17 | 2000-07-10 | 寳酒造株式会社 | 抗ヒトインフルエンザウイルス抗体 |
US5624949A (en) | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
JP3584990B2 (ja) * | 1994-05-09 | 2004-11-04 | タカラバイオ株式会社 | 抗ヒトインフルエンザウイルス抗体 |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
AU4474497A (en) | 1996-10-08 | 1998-05-05 | U-Bisys B.V. | Methods and means for selecting peptides and proteins having specific affinity for a target |
US6440736B1 (en) | 1998-10-16 | 2002-08-27 | U-Bisys B.V. | Altering the properties of cells or of particles with membranes derived from cells by means of lipid-modified proteinaceous molecules |
US20030161813A1 (en) | 1998-04-30 | 2003-08-28 | Ton Logtenberg | Altering the properties of cells or of particles with membranes derived from cells by means of lipid-modified proteinaceous molecules |
US7091324B2 (en) * | 1998-11-05 | 2006-08-15 | Board Of Trustees Of Leland Stanford Junior University | Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes |
ES2237420T5 (es) | 1999-04-15 | 2010-03-03 | Crucell Holland B.V. | Produccion de proteina recombinante en una celula humana. |
US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
EP1224943A1 (en) | 2001-01-19 | 2002-07-24 | Crucell Holland B.V. | Fibronectin as a tumor marker detected by phage antibodies |
EP1402025B1 (en) | 2001-06-15 | 2006-02-01 | Crucell Holland B.V. | Chimaeric phages |
US7070926B2 (en) | 2001-06-15 | 2006-07-04 | Crucell Holland B.V. | Chimaeric phages |
CA2481747A1 (en) * | 2002-04-12 | 2003-10-23 | Medimmune, Inc. | Recombinant anti-interleukin-9 antibodies |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
WO2005012337A2 (en) | 2003-07-15 | 2005-02-10 | Crucell Holland B.V. | Antigenic peptides of sars coronavirus and uses thereof |
KR101206206B1 (ko) | 2003-07-22 | 2012-11-29 | 크루셀 홀란드 비.브이. | 사스-코로나바이러스에 대한 결합분자 및 그것의 용도 |
WO2005063819A2 (en) | 2003-12-23 | 2005-07-14 | Crucell Holland B.V. | Human binding molecule against cd1a |
WO2005111623A1 (en) | 2004-05-17 | 2005-11-24 | Crucell Holland B.V. | Methods for diagnosis of acute myeloid leukemia |
DK1749029T3 (da) | 2004-05-27 | 2011-06-06 | Crucell Holland Bv | Bindemolekyler, der kan neutralisere rabiesvirus, og anvendelser deraf |
JP4852046B2 (ja) | 2004-10-12 | 2012-01-11 | クルセル ホランド ベー ヴェー | 癌の治療及び検出に用いる結合分子 |
US8106170B2 (en) | 2004-11-11 | 2012-01-31 | Crucell Holland B.V. | Compositions against SARS-coronavirus and uses thereof |
AU2005318171B2 (en) | 2004-12-20 | 2011-09-29 | Crucell Holland B.V. | Binding molecules capable of neutralizing West Nile virus and uses thereof |
JP4580338B2 (ja) | 2004-12-23 | 2010-11-10 | エーエスエムエル ネザーランズ ビー.ブイ. | リソグラフィ装置、エキシマ・レーザ、およびデバイス製造方法 |
AU2006245734C1 (en) | 2005-05-12 | 2012-05-24 | Crucell Holland B.V. | Host cell specific binding molecules capable of neutralizing viruses and uses thereof |
JP4758148B2 (ja) * | 2005-06-14 | 2011-08-24 | 泰三 宇田 | インフルエンザウイルスのヘマグルチニンに対する抗体酵素 |
US20090130652A1 (en) | 2005-06-23 | 2009-05-21 | Crucell Holland B.V. | Optimization of West Nile Virus Antibodies |
EP1907536B1 (en) | 2005-07-22 | 2010-04-07 | Crucell Holland B.V. | Cell line for producing coronaviruses |
WO2007031550A2 (en) | 2005-09-15 | 2007-03-22 | Crucell Holland B.V. | Method for preparing immunoglobulin libraries |
EA031202B1 (ru) | 2006-06-06 | 2018-11-30 | Янссен Вэксинс Энд Превеншн Б.В. | Антитело человека, обладающее фагоцитарной активностью против стафилококков, и его применение |
CA2654502C (en) | 2006-06-06 | 2015-07-14 | Crucell Holland B.V. | Human binding molecules having killing activity against enterococci and uses thereof |
MY170607A (en) | 2006-09-07 | 2019-08-20 | Crucell Holland Bv | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
US8802089B2 (en) | 2008-01-03 | 2014-08-12 | Genmab A/S | Monoclonal antibodies against CD32B |
US8148797B2 (en) | 2008-06-26 | 2012-04-03 | Taiwan Semiconductor Manufacturing Co., Ltd. | Chip pad resistant to antenna effect and method |
BRPI1012749B1 (pt) | 2009-05-11 | 2022-01-11 | Janssen Vaccines & Prevention B.V. | Anticorpo monoclonal humano, seu uso e seu método de produção, imunoconjugado, e composição farmacêutica |
CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
NZ772318A (en) | 2012-04-20 | 2023-06-30 | Merus Nv | Methods and means for the production of ig-like molecules |
-
2007
- 2007-09-06 MY MYPI2013000314A patent/MY170607A/en unknown
- 2007-09-06 KR KR20097005413A patent/KR101485197B1/ko active IP Right Grant
- 2007-09-06 JP JP2009527144A patent/JP5161882B2/ja active Active
- 2007-09-06 US US12/310,812 patent/US8192927B2/en active Active
- 2007-09-06 AU AU2007293662A patent/AU2007293662B2/en not_active Ceased
- 2007-09-06 MX MX2009002174A patent/MX2009002174A/es active IP Right Grant
- 2007-09-06 PL PL07803310T patent/PL2059532T3/pl unknown
- 2007-09-06 EP EP07803310A patent/EP2059532B1/en active Active
- 2007-09-06 EP EP20120153010 patent/EP2450377A1/en not_active Withdrawn
- 2007-09-06 CA CA2663388A patent/CA2663388C/en active Active
- 2007-09-06 EA EA200970255A patent/EA017203B1/ru unknown
- 2007-09-06 WO PCT/EP2007/059356 patent/WO2008028946A2/en active Application Filing
-
2009
- 2009-02-18 ZA ZA2009/01171A patent/ZA200901171B/en unknown
- 2009-03-03 IL IL197390A patent/IL197390A/en active IP Right Grant
- 2009-03-31 NO NO20091321A patent/NO20091321L/no not_active Application Discontinuation
- 2009-06-30 HK HK09105854A patent/HK1126799A1/xx not_active IP Right Cessation
-
2011
- 2011-12-09 US US13/315,475 patent/US8691223B2/en active Active
-
2012
- 2012-04-27 US US13/458,964 patent/US9011848B2/en active Active
- 2012-08-13 JP JP2012179593A patent/JP5701827B2/ja active Active
-
2013
- 2013-02-26 HR HRP20130163TT patent/HRP20130163T1/hr unknown
- 2013-10-01 US US14/043,677 patent/US9109017B2/en active Active
-
2015
- 2015-08-04 US US14/817,707 patent/US10005831B2/en active Active
-
2016
- 2016-11-29 IL IL249291A patent/IL249291B/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200970255A1 (ru) | Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение | |
EA201171383A1 (ru) | Человеческие связывающие молекулы, обладающие способностью нейтрализовывать вирус гриппа h3n2, и их применение | |
EA201491656A1 (ru) | Связывающие молекулы человека, способные связываться с вирусами гриппа в и нейтрализовать их, и их применения | |
EA201490288A1 (ru) | Связывающие молекулы человека, способные нейтрализовать вирусы гриппа a филогенетической группы 1 и филогенетической группы 2 и вирусы гриппа b | |
EA201101593A1 (ru) | КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА | |
EA200870594A1 (ru) | Связывающие человеческие молекулы с киллерной активностью в отношении энтерококков и их применение | |
EA201201650A1 (ru) | Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения | |
EA200602210A1 (ru) | Связывающие молекулы, способные нейтрализовать вирус бешенства, и их применение | |
EA201591091A1 (ru) | Антигенсвязывающие белки для bcma | |
CR20110079A (es) | Anticuerpos neutralizantes del virus anti-influenza y usos de los mismos | |
EA201500156A2 (ru) | Доставка антител посредством модульного домена распознавания | |
UY30776A1 (es) | Anticuerpos cd44 | |
EA200900514A1 (ru) | Антигенсвязывающие белки il-17 рецептора а | |
CO7151488A2 (es) | Anticuerpos de reacción cruzada anti-jagged1/jagged 2, anticuerpos anti-jagged activables y métodos de uso de los mismos | |
ECSP14001249A (es) | Inmunoenlazadores dirigidos contra el tnf | |
EA201790757A1 (ru) | Связывающие антиген cd27l белки | |
EA201500854A1 (ru) | Композиция, содержащая по меньшей мере две связывающие молекулы, нейтрализующие вирус гриппа а | |
BRPI0914799A2 (pt) | copoliamida semiaromática e seu processo de preparação | |
CO6351802A2 (es) | Anticuerpos para ccr2 | |
CR20110204A (es) | Moleculas de anticuerpo mejoradas | |
EA200702087A1 (ru) | Антитела против р-кадгерина | |
ATE553778T1 (de) | Für humanes hepcidin spezifische antikörper | |
BR112015012708A2 (pt) | anticorpos para bmp-6 | |
MY160435A (en) | A novel antiviral peptide against avian influenza virus h9n2 | |
MX343198B (es) | Moleculas de union humanas capaces de neutralizar el virus de la influenza h5n1 y usos de las mismas. |